Care partner-informed meaningful change thresholds for the Clinical Dementia Rating-Sum of Boxes for trials of early Alzheimer's disease

Alzheimers Dement. 2024 Sep;20(9):5889-5900. doi: 10.1002/alz.14050. Epub 2024 Jul 17.

Abstract

Introduction: Consensus definitions of meaningful within-patient change (MWPC) on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) are needed. Existing estimates use clinician-rated anchors in clinically diagnosed Alzheimer's disease (AD) populations. Incorporating the care partner perspective offers important insights, and evaluating biomarker-confirmed cohorts aligns estimates with ongoing trials.

Methods: Anchor-based analyses were conducted to evaluate MWPC on the CDR-SB in early AD (Tauriel; NCT03289143) using Caregiver Global Impression of Change in memory or daily activities.

Results: Across time points and anchors, mean CDR-SB changes associated with the "somewhat worse" category ranged from 1.50 to 2.12 in early AD, 1.07 to 2.06 in mild cognitive impairment-AD, and 1.79 to 2.25 in mild AD.

Discussion: The proposed ranges are appropriate to define meaningful progression on the CDR-SB in similar cohorts and support the interpretation of treatment benefit through MWPC analyses. Thresholds should be calibrated to the context of use; lower/higher thresholds may be applicable in studies of earlier/later disease over shorter/longer durations.

Highlights: Within-patient CDR-SB change thresholds are provided using caregiver-rated anchors. 1.5 to 2.5 points may be an appropriate range in early AD trials of similar durations. Cumulative distribution function plots illustrate the benefit of a given treatment. When selecting thresholds, the target population and study design should be considered.

Keywords: Alzheimer's disease; Caregiver Global Impression of Change – Alzheimer's Disease; Clinical Dementia Rating‐Sum of Boxes; Tauriel; activities of daily living; anchor‐based; clinical meaningfulness; cognition; function; meaningful change; mild cognitive impairment due to Alzheimer's disease; mild dementia due to Alzheimer's disease.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease* / diagnosis
  • Caregivers* / psychology
  • Clinical Trials, Phase II as Topic
  • Cognitive Dysfunction / diagnosis
  • Disease Progression*
  • Female
  • Humans
  • Male
  • Mental Status and Dementia Tests / standards
  • Mental Status and Dementia Tests / statistics & numerical data
  • Randomized Controlled Trials as Topic